Pantop%25252520d

# Pantoprazol ## Overview Pantoprazole is a proton pump inhibitor (PPI) that inhibits the H+/K+-ATPase enzyme system in the gastric parietal cell, suppressing both basal and stimulated gastric acid secretion. ## Primary Indications * Treatment of erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Short-term treatment of GERD-associated symptoms (e.g., heartburn). ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. * **Zollinger-Ellison Syndrome:** Starting dose 40 mg twice daily. Doses up to 240 mg daily have been used; individualize titration based on gastric acid output. * **GERD Symptoms:** 20 mg orally once daily. ## Pediatric Dosing * **GERD (5 years and older):** * Weight 15 kg to <40 kg: 20 mg once daily. * Weight ≥40 kg: 40 mg once daily. * *Note: Safety and efficacy in children <5 years have not been established.* ## Dose Adjustments * **Hepatic Impairment:** Reduce dose in severe hepatic impairment (Child-Pugh C). Consider every-other-day dosing or maximum 20 mg daily. * **Renal Impairment:** No dose adjustment required. ## Contraindications * Hypersensitivity to any component of the formulation or other substituted benzimidazoles (e.g., omeprazole, lansoprazole). * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, bone fractures (long-term, high-dose use). ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of ketoconazole, atazanavir, and mycophenolate mofetil. * **Methotrexate:** PPIs may increase serum levels of methotrexate, particularly in high-dose therapy. * **Clopidogrel:** Interaction significance is debated, but avoid if possible; pantoprazole has a lower inhibitory effect on CYP2C19 compared to omeprazole. ## Monitoring * Monitor for signs of *C. difficile* infection (unremitting diarrhea). * Monitor magnesium levels if on long-term therapy or concomitant drugs (e.g., diuretics). * Assess vitamin B12 status if on therapy >1 year. * Monitor renal function if acute interstitial nephritis is suspected. ## Clinical Pearls * **Administration:** Oral delayed-release tablets should be swallowed whole; do not crush or chew. IV administration must be via a dedicated line or Y-site, followed by a flush. * **Discontinuation:** Chronic users may experience rebound hypersecretion upon abrupt withdrawal; consider a gradual taper. * **Duration:** Utilize the lowest effective dose for the shortest duration necessary to minimize risk of adverse events. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice and institutional protocols may vary. Always verify current prescribing information, contraindications, and drug interactions against the official manufacturer's summary of product characteristics (SmPC) or your facility's drug reference system before administration.